Physician profile
David Amran
NPI 1841294261
$109,266.70
in general payments reported to CMS, 2019-2025
49 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,907 · 2020: $12K · 2021: $34K · 2022: $19K · 2023: $12K · 2024: $11K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $12K · Travel and Lodging: $936 · Education: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,750.00 |
| Food and Beverage | $12,379.53 |
| Travel and Lodging | $936.36 |
| Education | $392.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $73,511.74 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $15,161.24 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Novartis Pharmaceuticals Corporation | $4,828.40 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $3,499.98 | 2019-2024 | Dupixent |
| Genzyme Corporation | $2,464.98 | 2019-2025 | |
| Pfizer INC. | $814.96 | 2021-2025 | |
| Abbvie INC. | $748.05 | 2019-2025 | Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $691.69 | 2021-2025 | Cuvitru, Takhzyro, Eohilia |
| Optinose US, INC. | $688.04 | 2019-2025 | |
| Grifols USA, LLC | $644.59 | 2019-2025 | Xembify, Gamunex-C |
| Amgen INC. | $642.21 | 2021-2025 | Tezspire |
| Leo Pharma INC. | $573.63 | 2022-2025 | Adbry, Anzupgo |
| Kaleo, INC. | $568.32 | 2019-2024 | Auvi-Q |
| Pharming Healthcare, INC. | $554.11 | 2019-2025 | Ruconest |
| Genentech USA, INC. | $509.71 | 2019-2025 | Xolair |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $350.08 | 2019-2023 | |
| Organon LLC | $332.27 | 2025 | Vtama |
| Csl Behring | $272.25 | 2021-2025 | Hizentra |
| Sanofi-Aventis U.S. LLC | $252.54 | 2019-2024 | |
| Octapharma USA, INC. | $216.84 | 2022-2023 | Panzyga |
| Incyte Corporation | $216.49 | 2021-2024 | Opzelura |
| Blueprint Medicines Corporation | $200.96 | 2023-2025 | Ayvakit |
| Galderma Laboratories, L.P. | $186.48 | 2024-2025 | Nemluvio, Aklief |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.69 | 2019-2022 | |
| Mylan Specialty L.P. | $127.71 | 2021-2023 | Yupelri |
| Hospira, INC. | $126.21 | 2024-2025 | |
| Sanofi Pasteur INC. | $111.37 | 2019-2023 | |
| Ars Pharmaceuticals Operations, INC. | $103.48 | 2025 | Neffy |
| Verona Pharma, INC. | $85.02 | 2025 | Ohtuvayre |
| Ionis Pharmaceuticals, INC. | $58.38 | 2025 | Dawnzera |
| Gc Biopharma USA, INC. | $58.11 | 2025 | Alyglo |
| Alk-Abello, INC | $49.82 | 2019-2021 | |
| Tersera Therapeutics LLC | $49.73 | 2024 | Quzyttir |
| Hikma Pharmaceuticals USA | $40.09 | 2022-2024 | Ryaltris |
| Azurity Pharmaceuticals, INC. | $39.25 | 2025 | Alvesco |
| Biocryst US Sales Co., LLC | $36.71 | 2022-2024 | Orladeyo |
| Adma Biomanufacturing LLC | $30.76 | 2021 | |
| Lilly USA, LLC | $29.52 | 2024-2025 | Ebglyss |
| Aytu Biopharma, INC. | $28.54 | 2020-2024 | Karbinal |
| Cycle Pharmaceuticals INC | $26.41 | 2024 | Sajazir |
| Pulmonx Corporation | $25.49 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Xeris Pharmaceuticals, INC. | $21.17 | 2023 | Gvoke Hypopen |
| X4 Pharmaceuticals, INC. | $20.27 | 2024 | Xolremdi |
| Merck Sharp & Dohme LLC | $19.71 | 2023 | |
| Horizon Therapeutics Plc | $19.16 | 2019 | |
| Philips North America LLC | $19.04 | 2019 | |
| Phadia US INC. | $17.12 | 2020 | |
| Insmed, INC. | $15.38 | 2024 | Arikayce |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Amran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.